luminal type a breast cancer

Optimal Ki67 cut-off for luminal breast cancer prognostic

 · EPIDEMIOLOGY Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation a large case series study with a long-term follow-up Sara Bustreo2 • Simona Osella-Abate1 • Paola Cassoni1 • Michela Donadio2 • Mario Airoldi3 • Fulvia Pedani3 • Mauro Papotti4 • Anna Sapino1 5 • Isabella Castellano1 Received 14 March 2016/Accepted 26 April 2016/Published online 7 May 2016

Frontiers Luminal A Breast Cancer Co-expression Network

 · Luminal A is the most common breast cancer molecular subtype in women worldwide. These tumors have characteristic yet heterogeneous alterations at the genomic and transcriptomic level. Gene co-expression networks (GCNs) have contributed to better characterize the cancerous phenotype. We have previously shown an imbalance in the proportion of intra-chromosomal (cis-) over inter

Breast Cancer Cell Line Classification and Its Relevance

 · Luminal breast cancer cell lines are characterized by positive ER and/or PR expression despite the existence of a few exceptional cases such as IBEP-1 and IBEP-3 where PR positivity drives their luminal phenotype. This type of cell lines exhibits high expression of a panel of luminal feature associated genes/proteins including e.g. ESR1

GATA3 mutations define a unique subtype of luminal‐like

 · INTRODUCTION. Breast cancer is the most frequently diagnosed cancer among females accounting for approximately 23 of total cancer cases and approximately 14 of cancer deaths. 1 Clinically this heterogeneous disease is categorized into 4 basic therapeutic groups including luminal A luminal B human epidermal growth factor receptor 2 (HER2)-enriched and basal-like.

Prognostic parameters of luminal A and luminal B intrinsic

 · Prognosis of breast cancer and success of therapeutic interventions largely rely on the clinico-pathologic and biological characteristics of the tumor and vary due to the heterogeneous nature of breast cancers. The aim of this study was to determine the frequency and prognostic parameters of luminal breast cancers in our population to devise targeted and personalized therapeutic regimens

The invasive lobular carcinoma as a prototype luminal A

 · The invasive lobular carcinoma (ILC) known to be the second most common histologic subtype of invasive breast cancer following the invasive ductal carcinoma (IDC) constitutes 8-14 of all breast cancers in most Western reports 1–3 .However in Asia it appears to be very low accounting for only 2-4 in Korea 4–6 and 1-4 in Japan 7 8 .

Luminal A Breast Cancer and Molecular Assays A Review

 · Introduction. Breast cancer is a heterogeneous disease with treatment decisions and prognosis traditionally guided by immunohistochemistry (IHC) markers such as estrogen receptor (ER) progesterone receptor (PR) human epidermal growth receptor 2 (HER2) and Ki67 (a proliferation index marker) along with tumor size tumor grade and nodal status.

Luminal A and luminal B (HER2 negative) subtypes of breast

 · The St Gallen International Expert Consensus 2011 has proposed a new classification system for breast cancer. The purpose of this study was to elucidate the relationship between the breast cancer subtypes determined by the new classification system and genomic characteristics. Invasive breast cancers (n = 363) were immunohistochemically classified as follows 111 (30.6 ) as luminal A

Can Oncotype DX Recurrence Score (RS) be used in Luminal A

 · 40. Background The 2011 St Gallen guidelines recommend the use of Ki67 as a surrogate marker for luminal A and Luminal B breast cancer subtypes. Pts with luminal B subtypes should be treated with adjuvant chemotherapy. The guidelines also recognize the Oncotype DX RS as a predictor of chemotherapy benefit. The aim of this study is to assess the distribution of the RS in luminal A and luminal

The genetics of luminal A-like breast cancer (Zhang 2020)

 · Luminal A-like is a subtype of breast cancer with the best prognosis and it accounts for 30-45 breast cancer cases. It is characterized by cancerous cells originating in the inner or luminal cells that line the mammary ducts. Moreover this breast cancer subtype is characterized by a cancerous growth in response to excess estrogen.

Identification of a Low-Risk Luminal A Breast Cancer

 · The first large-scale breast cancer gene expression profiling studies classified tumors into four major intrinsic subtypes luminal A luminal B HER2 enriched and basal like. 12 27 Luminal A was the most favorable group with 10-year overall survival rates of approximately 95 and high local relapse-free rates of 92 after breast RT. 17 This

A high-risk luminal A dominant breast cancer subtype with

Purpose Breast cancer is a heterogeneous disease and although advances in molecular subtyping have been achieved in recent years most subtyping strategies target individual genes independent of one another and primarily concentrate on proliferative markers. The contributions of biological processes and immune patterns have been neglected in breast cancer subtype stratification.

Precise discrimination of Luminal A breast cancer subtype

Precise discrimination of breast cancer remains a challenge in clinical medicine which depends on the development of novel specific molecular probes. However the current technologies and antibodies cannot achieve precise discrimination of breast cancer subtypes very well. To address this problem a

Molecular Subtypes of Breast Cancer

 · Luminal A breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive) HER2 negative and has low levels of the protein Ki-67 which helps control how fast cancer cells grow. Luminal A cancers are low-grade tend to

Luminal B breast cancer subtype displays a dicotomic

 · Luminal breast cancer subtypes display distinct clinicopathologic characteristics. With the aim of assessing the epigenetic heterogeneity among BC subtypes with similar histologically characteristics only tumor size between 2 and 3 cm and histological grade between 2 and 3 were included in the current study.

Luminal A Breast Cancer and Molecular Assays A Review

 · Introduction. Breast cancer is a heterogeneous disease with treatment decisions and prognosis traditionally guided by immunohistochemistry (IHC) markers such as estrogen receptor (ER) progesterone receptor (PR) human epidermal growth receptor 2 (HER2) and Ki67 (a proliferation index marker) along with tumor size tumor grade and nodal status.

Luminal-Type Breast Cancer Correlation of Apparent

 · Luminal-type (estrogen receptor–positive) breast cancer is the most frequent subtype (∼70 of cases). Luminal A is defined as a low-proliferation subtype (Ki-67 < 14) and luminal B is defined as a high-proliferation subtype (Ki-67 ≥ 14) as assessed by means of the Ki-67 LI (1–3). Luminal A is not responsive to chemotherapy but is

Breast cancer types What your type meansMayo Clinic

 · Breast cancer groups include Group 1 (luminal A). This group includes tumors that are ER positive and PR positive but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy. Group 2 (luminal B). This type includes tumors that are ER positive PR negative and HER2 positive.

Ki-67 expression in luminal type breast cancer and its

Introduction. Breast cancer is the most common malignancy in women accounting for 20 of total malignant tumors in females ().Numerous studies have shown that breast cancer is a highly heterogeneous malignancy with significant differences in histomorphological features immunophenotype biological behavior and response to treatment.Currently breast cancer is classified as luminal tumors

Can Oncotype DX Recurrence Score (RS) be used in Luminal A

 · 40. Background The 2011 St Gallen guidelines recommend the use of Ki67 as a surrogate marker for luminal A and Luminal B breast cancer subtypes. Pts with luminal B subtypes should be treated with adjuvant chemotherapy. The guidelines also recognize the Oncotype DX RS as a predictor of chemotherapy benefit. The aim of this study is to assess the distribution of the RS in luminal A and luminal

A high-risk luminal A dominant breast cancer subtype with

Purpose Breast cancer is a heterogeneous disease and although advances in molecular subtyping have been achieved in recent years most subtyping strategies target individual genes independent of one another and primarily concentrate on proliferative markers. The contributions of biological processes and immune patterns have been neglected in breast cancer subtype stratification.

Can Oncotype DX Recurrence Score (RS) be used in Luminal A

 · 40. Background The 2011 St Gallen guidelines recommend the use of Ki67 as a surrogate marker for luminal A and Luminal B breast cancer subtypes. Pts with luminal B subtypes should be treated with adjuvant chemotherapy. The guidelines also recognize the Oncotype DX RS as a predictor of chemotherapy benefit. The aim of this study is to assess the distribution of the RS in luminal A and luminal

Can Oncotype DX Recurrence Score (RS) be used in Luminal A

 · 40. Background The 2011 St Gallen guidelines recommend the use of Ki67 as a surrogate marker for luminal A and Luminal B breast cancer subtypes. Pts with luminal B subtypes should be treated with adjuvant chemotherapy. The guidelines also recognize the Oncotype DX RS as a predictor of chemotherapy benefit. The aim of this study is to assess the distribution of the RS in luminal A and luminal

Luminal A Main Line Health

 · Luminal A breast cancer the most common type of breast cancer reacts to hormones and uses them to grow but doesn t have a HER2 gene. Luminal A breast cancer grows very slowly and doesn t often spread to other cells. Women with luminal A breast cancer have the best chance for a cure and least chance of cancer coming back than any other type of breast cancer.

Prognostic parameters of luminal A and luminal B intrinsic

 · Prognosis of breast cancer and success of therapeutic interventions largely rely on the clinico-pathologic and biological characteristics of the tumor and vary due to the heterogeneous nature of breast cancers. The aim of this study was to determine the frequency and prognostic parameters of luminal breast cancers in our population to devise targeted and personalized therapeutic regimens

Distinguishing Low-Risk Luminal A Breast Cancer Subtypes

 · Low-risk luminal A subtype was defined as negative for both Ki-67 and p53 (luminal A ki-67- p53- ) and others subtypes were considered to be high-risk luminal A breast cancer. A cut-off value of 10 for p53 was a good predictor of clinical outcome in all patients and luminal A breast cancer patients.

Value of Breast Cancer Molecular Subtypes and Ki67

 · Luminal A type breast cancer is the most common and least aggressive type with the lowest mortality rate. 33 In addition luminal A mortality rates were reported to be constant over time with mortality rates of luminal B HER2-positive and nonluminal subtypes tending to peak within 5 years after diagnosis which then declined over time 34

Luminal A Breast Cancer and Molecular Assays A Review

 · Introduction. Breast cancer is a heterogeneous disease with treatment decisions and prognosis traditionally guided by immunohistochemistry (IHC) markers such as estrogen receptor (ER) progesterone receptor (PR) human epidermal growth receptor 2 (HER2) and Ki67 (a proliferation index marker) along with tumor size tumor grade and nodal status.

Luminal A and luminal B (HER2 negative) subtypes of breast

 · The St Gallen International Expert Consensus 2011 has proposed a new classification system for breast cancer. The purpose of this study was to elucidate the relationship between the breast cancer subtypes determined by the new classification system and genomic characteristics. Invasive breast cancers (n = 363) were immunohistochemically classified as follows 111 (30.6 ) as luminal A

Distinguishing Low-Risk Luminal A Breast Cancer Subtypes

 · Low-risk luminal A subtype was defined as negative for both Ki-67 and p53 (luminal A ki-67- p53- ) and others subtypes were considered to be high-risk luminal A breast cancer. A cut-off value of 10 for p53 was a good predictor of clinical outcome in all patients and luminal A breast cancer patients.

Efficacy of chemotherapy for lymph node-positive luminal A

 · Luminal type A has better prognosis than other breast cancer subtypes. Oncologists define luminal A as estrogen receptor (ER) > 1 progesterone receptor (PR) ≥ 20 breast cancer with negative human epidermal growth factor receptor-2 (HER2) and Ki-67 < 14 of clinical cases 4 .